Livingstone acted as financial advisor to Steril Verona S.r.l. (“Steril Verona”), supporting the company and its majority shareholders in a corporate reorganization process aimed at facilitating the exit of the minority shareholder and in securing the financing required to support the company’s next phase of industrial development.
Founded in 1997, Steril Verona is a family-owned company specializing in ethylene oxide (EO) sterilization services for leading manufacturers of medical devices, healthcare instruments, and pharmaceutical packaging. The company operates three dedicated sterilization facilities in the Verona area, covering a total surface area of approximately 31,000 square meters.
Livingstone supported the company throughout the corporate reorganization process related to the minority shareholder’s exit, assisted in the preparation of the business plan together with management to define the assumptions underpinning the company’s new growth strategy, and managed discussions and negotiations with a selected group of leading financial institutions to structure a financing package supporting both the transaction and future growth initiatives.
“We are pleased to have once again supported the shareholders of Steril Verona in this new phase of development, building on a relationship that spans more than five years. This transaction further demonstrates the strength of our long-standing partnership and our ongoing commitment to supporting a dynamic and innovative company in its most important strategic decisions and growth initiatives,” said Umberto Rossi, Partner at Livingstone.
This project further demonstrates Livingstone’s ability to support healthcare companies not only on M&A transactions, but also through high-value strategic and debt advisory services.
